BRIEF-Esperion Partner Otsuka Launches Nexletol In Japan

Reuters

Nov 21

Nov 21 (Reuters) - Esperion Therapeutics Inc ESPR.O:

ESPERION PARTNER OTSUKA LAUNCHES NEXLETOL® IN JAPAN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
ESPERION THERAPEUTICS: UNDER AGREEMENT, ESPERION WILL RECEIVE $90 MILLION IN A NEAR TERM PAYMENT AS A RESULT OF THE RECENT OTSUKA ACHIEVEMENTS
ESPERION THERAPEUTICS: ALSO ELIGIBLE TO RECEIVE ADDITIONAL SALES MILESTONE PAYMENTS BASED ON TOTAL NET SALES ACHIEVEMENTS BY OTSUKA IN JAPAN

Source text: ID:nGNX5G7vm8

Further company coverage: ESPR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2585145382"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585145382\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585145382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585145382","market":"us","top_or_hot":-1,"title":"BRIEF-Esperion Partner Otsuka Launches Nexletol In Japan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Esperion Partner Otsuka Launches Nexletol In Japan</title></head><body><p><span>Nov 21 (Reuters)</span><span> - </span>Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>ESPR.O</span>:</p><ul><li><p>ESPERION PARTNER OTSUKA LAUNCHES NEXLETOL® IN JAPAN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA</p></li><li><p>ESPERION THERAPEUTICS: UNDER AGREEMENT, ESPERION WILL RECEIVE $90 MILLION IN A NEAR TERM PAYMENT AS A RESULT OF THE RECENT OTSUKA ACHIEVEMENTS</p></li><li><p>ESPERION THERAPEUTICS:  ALSO ELIGIBLE TO RECEIVE ADDITIONAL SALES MILESTONE PAYMENTS BASED ON TOTAL NET SALES ACHIEVEMENTS BY OTSUKA IN JAPAN</p></li></ul><p>Source text: <span>ID:nGNX5G7vm8</span></p><p>Further company coverage: <span>ESPR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Esperion Partner Otsuka Launches Nexletol In Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Esperion Partner Otsuka Launches Nexletol In Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-21 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Esperion Partner Otsuka Launches Nexletol In Japan</title></head><body><p><span>Nov 21 (Reuters)</span><span> - </span>Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>ESPR.O</span>:</p><ul><li><p>ESPERION PARTNER OTSUKA LAUNCHES NEXLETOL® IN JAPAN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA</p></li><li><p>ESPERION THERAPEUTICS: UNDER AGREEMENT, ESPERION WILL RECEIVE $90 MILLION IN A NEAR TERM PAYMENT AS A RESULT OF THE RECENT OTSUKA ACHIEVEMENTS</p></li><li><p>ESPERION THERAPEUTICS:  ALSO ELIGIBLE TO RECEIVE ADDITIONAL SALES MILESTONE PAYMENTS BASED ON TOTAL NET SALES ACHIEVEMENTS BY OTSUKA IN JAPAN</p></li></ul><p>Source text: <span>ID:nGNX5G7vm8</span></p><p>Further company coverage: <span>ESPR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA1YXTQD:1","article_id":"2585145382","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585145382","pubTimestamp":1763731255,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Esperion Partner Otsuka Launches Nexletol In JapanNov 21 (Reuters) - Esperion Therapeutics Inc ESPR.O:ESPERION PARTNER OTSUKA LAUNCHES NEXLETOL IN JAPAN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ESPR":"Esperion Therapeutics Inc."},"translate_title":"简介-Esperion合作伙伴Otsuka在日本推出Nexletol","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":0.9},"content_text":"BRIEF-Esperion Partner Otsuka Launches Nexletol In JapanNov 21 (Reuters) - Esperion Therapeutics Inc ESPR.O:ESPERION PARTNER OTSUKA LAUNCHES NEXLETOL® IN JAPAN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIAESPERION THERAPEUTICS: UNDER AGREEMENT, ESPERION WILL RECEIVE $90 MILLION IN A NEAR TERM PAYMENT AS A RESULT OF THE RECENT OTSUKA ACHIEVEMENTSESPERION THERAPEUTICS:  ALSO ELIGIBLE TO RECEIVE ADDITIONAL SALES MILESTONE PAYMENTS BASED ON TOTAL NET SALES ACHIEVEMENTS BY OTSUKA IN JAPANSource text: ID:nGNX5G7vm8Further company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}